MicroRNA-193b在初治白血病患者的表达及意义

本研究旨在检测白血病患者microRNA-193b(miR-193b)的表达水平并探讨其意义。采用实时荧光定量PCR方法检测初治白血病患者miR-193b的相对表达水平,分析其在不同类型白血病中的表达差异及其与部分实验室指标和化疗反应的关系。结果表明:慢性髓系白血病(CML)和急性早幼粒细胞白血病(APL)患者与正常对照组miR-193b的表达相比,其差异均无统计学意义(P>0.05);AML(除外APL)、ALL患者miR-193b的表达均低于正常对照组,其差异有统计学意义(P<0.05)。在AML(除外APL)患者中,miR-193b表达水平与患者外周血白细胞计数及细胞CD34表达无明显相关,但是与患者的治疗反应呈负相关(P<0.05)。结论:AML(除外APL)患者中miR-193b表达水平可能与AML细胞的化疗敏感性相关。miR-193b可能是AML(除外APL)治疗的一个新靶点。

MicroRNA-193b Expression in Newly Diagnosed Leukemia Patients and Its Significance

This study was aimed to quantitatively detect the levels of microRNA-193b（miR-193b） in leukemia patients and explore its significance.Real time fluorescent quantitative PCR was used to detect the relative expression level of miR-193b.The expression changes of miR-193b in various types of leukemia were analyzed.Then the relationship among miR-193b expression,parts of laboratory index and the response to chemotherapy was analyzed as well.The results showed that miR-193b expression level in acute promyelocytic leukemia（APL） and chronic myeloid leukemia（CML） patients was not lower than that in normal group（P〈0.05）.Except for APL,miR-193b expression level in acute myeloid leukemia（AML） patients was lower than that in normal group（P〈0.05）.In AML（except for APL） patients,there was no correlation between white blood cell count（P〈0.05）,the expression of CD34（P〈0.05） and miR-193b expression level,but there was negative correlation between chemotherapy response and miR-193b expression level（P〈0.05）.It is concluded that miR-193b expression level may be correlated with susceptibility of cells to chemotherapy in AML（except for APL） patients.miR-193b maybe become a new target in AML（except for APL） therapy.